Pharmaceutical News

RSS

Eisai enters strategic drug discovery collaboration with FORMA Therapeutics

Eisai Inc., the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., and FORMA Therapeutics announced today that the two companies have signed a strategic drug discovery collaboration.

17 Nov 2010

FDA partners with CDC to kick off Get Smart about Antibiotics Week

This year, millions of antibiotics will be prescribed. Antibiotics can be used to treat bacterial infections; however, they are commonly over-prescribed. Patients sometimes ask their health care professional to prescribe antibiotic drugs for viral infections, like the common cold, despite the fact that they will not work and may lead to potentially harmful side effects. The misuse of antibiotics has contributed to one of the world's most pressing public health problems today, antibiotic resistance.

17 Nov 2010

Type 2 diabetes market in Mexico to grow to $1.22 billion in 2014: Report

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that the type 2 diabetes market in Mexico will grow to $1.22 billion in 2014. Drivers of this growth include increasing prevalent population, expanding medical insurance coverage as well as the launch and use of new drugs in the market.

17 Nov 2010

Optivia, UCSF receive SBIR grant to develop transporter-based assay system

Optivia Biotechnology Inc., a leading provider of in vitro transporter assay services, today announced that the company and the University of California, San Francisco (UCSF), have received a Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to develop an innovative system for characterizing the role transporter proteins play in the disposition of drugs by the liver.

16 Nov 2010

UCSF, Pfizer announce partnership to accelerate translation of biomedical research

UCSF and Pfizer, Inc. have formed a new partnership to accelerate the translation of biomedical research into effective new medications and therapies for patients.

16 Nov 2010

Yukon receives grant under QTDP program for SmartMix delivery platform

Yukon Medical, LLC, a medical device firm located in Research Triangle Park, NC, is proud to announce it has received a grant under the 2010 Qualifying Therapeutic Discovery Project (QTDP) for their SmartMix delivery platform.

16 Nov 2010

FDA grants Impax final approval for generic Allegra-D ANDA

Impax Laboratories, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted final approval of the Company's Abbreviated New Drug Application (ANDA) for the generic version of Allegra-D® (Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended-release) 60mg/120mg tablets. The Company is preparing for product launch through Global Pharmaceuticals, Impax's generic division.

16 Nov 2010

Patrys announces capital raising of $3.2 million and share purchase plan

Patrys Limited (ASX: PAB; Company), a biotechnology company focused on the development of revolutionary new treatments for cancer, is pleased to announce a successful capital raising of approximately $3.2 million, which was conducted via a private placement.

16 Nov 2010

Can Pfizer rescue hormonal replacement therapy?

In a market still plagued with safety concerns, Pfizer has an opportunity to restore market growth for hormonal replacement therapy (HRT) with its new combination product, Aprela. To do this it must rebuild public and general practitioner confidence in the therapy area, says independent market analyst, Datamonitor.

16 Nov 2010

Color of tablet appears to be integral component for OTC product

According to recent research the color, shape, taste and even name of a tablet or pill can have an effect on how patients feel about their medication. Choose an appropriate combination and the placebo effect gives the pill a boost, improves outcomes and might even reduce side effects. Now, researchers at the University of Bombay, New Mumbai, India, have surveyed users of over-the-counter (OTC) medication to find out just how much the color of a tablet influences patient choice.

16 Nov 2010

Study shows asthma drugs can treat aortic aneurysm

A new study from the Swedish medical university Karolinska Institutet shows that asthma drugs are a potential treatment for aortic aneurysm. These drugs, which block cysteinyl-leukotrienes, could reduce the break down of vessel wall tissue and the dilation of the aortic wall, and thus the risk of its rupturing.

16 Nov 2010

Orexo's Abstral sales increases 345% to £14.1m

Orexo AB announces that its sales partner in the EU and USA for Abstral, ProStrakan Group plc yesterday issued its interim report, which gave further information on progress with Abstral, Orexo's leading sublingual fentanyl product for treatment of breakthrough cancer pain.

16 Nov 2010

New mechanism breaks drug resistance in ovarian cancer

Drug resistance is a major obstacle in curing ovarian cancer but new research from the Centenary Institute has discovered a treatment that kills ovarian cancer cells in a new way that can break the resistance mechanism.

16 Nov 2010

FDA announces program to facilitate development of external defibrillators to treat abnormal heart rhythms

The U.S. Food and Drug Administration today announced a program aimed at facilitating the development of safer, more effective external defibrillators used to treat abnormal heart rhythms through improved design and manufacturing practices. External defibrillators are medical devices designed to diagnose life-threatening abnormal heart rhythms and treat them by delivering electrical energy to the heart to restore its normal rhythm.

16 Nov 2010

Hospira launches two-gram vial of gemcitabine hydrochloride for injection

Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced it has launched a two-gram vial of gemcitabine hydrochloride for injection.

16 Nov 2010

District Court judgment favors Otsuka in Abilify patent litigation

Otsuka Pharmaceutical Co., Ltd. and Otsuka Holdings, Co., Ltd., the parent company of Otsuka Pharmaceutical Co., Ltd., announced today that the U.S. District Court for the District of New Jersey issued its judgment dated November 15, 2010 in favor of Otsuka Pharmaceutical Co., Ltd. in its patent litigation against several companies seeking FDA approval to market generic copies of Abilify.

16 Nov 2010

Study finds two-thirds of asthma patients take combined ICS/LABA treatment

Despite national guidelines recommending that inhaled corticosteroid (ICS) be used alone as the preferred treatment for patients with mild persistent asthma, a new study finds that nearly two-thirds of these patients are taking more costly drugs that combine an ICS and a long-acting beta agonist (LABA) with no apparent additional clinical benefit noted based on pharmacy and medical claims.

16 Nov 2010

National campaign to highlight significance of antibiotic resistance

Antibiotic resistance is one of the world's most pressing public health threats. To bring attention to this increasing problem, the Centers for Disease Control and Prevention and other government partners will observe its third annual Get Smart About Antibiotics Week on Nov. 15-21, 2010.

16 Nov 2010

Researchers develop new vaccine delivery system for rotavirus infection

Researchers have developed a promising new approach to vaccination for rotavirus, a common cause of severe diarrheal disease that is responsible for approximately 500,000 deaths among children in the developing world every year.

16 Nov 2010

New inhalable dry powder treatment for lung cancer shows significant increase in survival rates: Research

A new inhalable dry powder treatment for lung cancer shows a significant increase in survival rates and is far less invasive than current treatment options, which frequently include radiation and surgery. This research is being presented at the 2010 International Pharmaceutical Federation Pharmaceutical Sciences World Congress in association with the American Association of Pharmaceutical Scientists Annual Meeting and Exposition in New Orleans, La., Nov. 14-18.

16 Nov 2010